Generalized Lipodystrophy

3

Review clinical trials related to Generalized Lipodystrophy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the body at different times. This is a 2-part study: Part A is an efficacy study in pediatric and adult participants, Part B is a safety and pharmacokinetic study in pediatric participants. The study is researching several other questions, including: * How mibavademab affects the amount of sugar in the blood * How mibavademab affects the amount of fat (triglycerides) in the blood * How mibavademab affects the amount of fat that has built up in the liver * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Participants needed: 28
Trial details
Phase: Phase 3Age: 2+Biological sex: AllType: InterventionalSponsor: Regeneron PharmaceuticalsUpdated: Jul 13, 2026Locations: 3
Eligibility criteria

Participants ≥2 years of age at screening [+9]

Has a current diagnosis of familial or acquired partial lipodystrophy or autoimm... [+8]

Status: Recruiting

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the body at different times. This is a 2-part study: Part A is an efficacy study in pediatric and adult participants, Part B is a safety and pharmacokinetic study in pediatric participants. The study is researching several other questions, including: * How mibavademab affects the amount of sugar in the blood * How mibavademab affects the amount of fat (triglycerides) in the blood * How mibavademab affects the amount of fat that has built up in the liver * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Participants needed: 28
Trial details
Phase: Phase 3Age: 2+Biological sex: AllType: InterventionalSponsor: Regeneron PharmaceuticalsUpdated: May 6, 2026Locations: 2
Eligibility criteria

Participants ≥2 years of age at screening [+9]

Has a current diagnosis of familial or acquired partial lipodystrophy or autoimm... [+8]

Status: Recruiting

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

Participants needed: 15
Trial details
Phase: Phase 3Age: Up to 5Biological sex: AllType: InterventionalSponsor: Amryt PharmaUpdated: Jan 20, 2026Locations: 12
Eligibility criteria

Confirmed diagnosis of Generalised Lipodystrophy [+1]

Weight <9 kg at Screening (Visit 1)